Jade Biosciences

We’re attending the TD Cowen Inc. 45th Annual Health Care Conference from March 3-5 and Jefferies Biotech on the Beach Summit from March 11-12. Message us to schedule a meeting or connect at the events. https://lnkd.in/gBn5GWRf

Did you know?     APRIL, also known as A PRoliferation Inducing Ligand, is a protein that promotes production of IgA.     IgA is a type of antibody produced by the immune system, including gd-IgA, a form of IgA that can be harmful to the kidney in IgA nephropathy, a chronic kidney disease resulting from inflammation and damage that can impair kidney function over time.   By reducing production of the harmful IgA, it may be possible to reduce kidney damage and preserve kidney function. Learn more about the work Jade is doing: https://lnkd.in/grcGny3H     Share this post with anyone curious about innovative therapies in development for kidney diseases.    #IgAN #AutoimmuneDiseases #KidneyDisease       For additional important information regarding Jade and our pending business combination, see the amended Form S-4 filed by Aerovate Therapeutics, Inc. here: https://lnkd.in/gGGkrfPA  

At Jade Biosciences, advancing science isn’t just what we do—it’s how we make a difference. Our team is driven by a shared mission: to improve the lives of patients with autoimmune diseases through innovative therapies.    We’re growing and looking for passionate, purpose-driven individuals to join us. If you’re ready to bring your expertise and energy to a team committed to making an impact, send us a message.     Tag someone who inspires you in their work or share this post with someone looking to take their career to the next level in biotech.    #BiotechCareers #TeamJade #ScienceWithPurpose #Culture #JoinOurTeam   

IgA nephropathy is more than just a kidney condition—it’s a chronic autoimmune disease. Here’s what you need to know:    🔹 What is IgAN?  IgAN occurs when an abnormal form of IgA—a type of antibody produced by the immune system—forms immune complexes and is deposited in the kidneys, causing damage. Over time, this can lead to declining kidney function and, in severe cases, kidney failure requiring dialysis or transplant.    🔹 Who does it affect?  Often diagnosed in late teens to early thirties, IgAN has no approved treatments that directly reduce the harmful form of IgA or stabilize kidney function.    At Jade Biosciences, we are working to change that. We are developing a medicine designed to target IgAN at its source, offering hope for patients living with this disease. #IgAN #KidneyHealth #AutoimmuneDisease #InnovationInHealth    -------------------   For additional important information regarding Jade and our pending business combination, see the amended Form S-4 filed by Aerovate Therapeutics, Inc. here: https://lnkd.in/gGGkrfPA 

Our team is heading to the J.P. Morgan Healthcare Conference 2025 next week. If you'll be there too, let's connect. Drop us a message or comment below to schedule time to meet with CEO Tom Frohlich and CSO, Head of R&D Andrew King. #JPM2025 #Biotech #Pharma  

CEO Tom Frohlich will present Jade Biosciences’ progress in autoimmune disease treatment at the Stifel Healthcare Conference on November 18 and Jefferies London Healthcare Conference on November 20.  If you're attending, come connect with our team on-site. Read more: https://lnkd.in/g7UyyGsB #AutoimmuneDisease #Biotech #Healthcare

Jade Biosciences is merging with Aerovate Therapeutics to create a company focused on advancing breakthrough therapies for #autoimmune diseases. With our lead program, JADE-001, anticipated to move into the clinic in the second half of 2025 and strong financial backing, we’re well positioned to make meaningful progress with our programs. Read our press release for all the details: https://lnkd.in/gnKy4NVC

We’re excited to welcome Tom Frohlich as our new CEO and Hetal Kocinsky, M.D. as CMO. Their combined expertise in drug development and business strategy will fuel our mission to deliver breakthrough therapies for autoimmune diseases. With a newly formed Board of Directors and $95M in expanded funding, we’re ready to accelerate the next phase of growth of Jade. Learn more 👉 https://lnkd.in/d2BYk-2D #biotech #leadership #autoimmunediseases

Excited to announce the launch of Jade Biosciences today with $80M in financing from a strong slate of investors to fuel a pipeline of potentially best-in-class therapies for people living with autoimmune diseases. Meet our Chief Scientific Officer, Andrew King, D.V.M., Ph.D., who brings 15+ years of leadership experience across biotech and pharma. The funding will be used to support our mission of delivering transformative therapies across inflammation and immunology. Read the release: https://lnkd.in/e7q8vzES #AutoimmuneDisease #Biotech #Launch #Financing